{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2294","pValueComment":"The test of treatment effect was conducted at a 2-sided alpha level of 0.10.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the 90% confidence interval was not calculable.","groupId":"OG000","lowerLimit":"9.3","upperLimit":"NA","value":"12.9"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"19.4","value":"6.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"Overall survival (OS) time is defined as the time from the date of randomization to the date of death from any cause. For participants not known to have died as of the data cut-off date, OS time was censored at the last contact date the participant was known to be alive prior to the data cut-off date. OS was summarized using Kaplan-Meier estimates.","dispersionType":"90% Confidence Interval","groups":[{"description":"Cycles 1-4 (21-day cycle):\n\nBefore 25 Oct 2012:\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nDay 2: LY2603618 dose determined from phase 1 (275 mg)\n\nAfter 25 Oct 2012:\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nAfter 4 cycles, participants may have continued on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion was met.\n\nMaintenance therapy (every 21 days):\n\nBefore 25 Oct 2012:\n\nDay 1: pemetrexed 500 mg/m\\^2\n\nDay 2: LY2603618 dose determined from phase 1 (275 mg)\n\nAfter 25 Oct 2012:\n\nDay 1: pemetrexed 500 mg/m\\^2\n\nIf, as of 25 Oct 2012, the participant was in maintenance therapy and randomized to the experimental arm, the participant was eligible to continue with pemetrexed/LY2603618 therapy if the investigator deemed it was in the participant's best interest and the participant consented.\n\nPemetrexed, cisplatin, and LY2603618 were administered IV over 10 minutes, 1 hour, and 1 hour, respectively.","id":"OG000","title":"Phase 2: Pemetrexed + Cisplatin + LY2603618"},{"description":"Cycles 1-4 (21-day cycle):\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nAfter 4 cycles, participants may have continued on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion was met.\n\nMaintenance therapy (every 21 days):\n\nDay 1: pemetrexed 500 mg/m\\^2\n\nPemetrexed was administered IV over 10 minutes, and cisplatin was administered IV over 1 hour.","id":"OG001","title":"Phase 2: Pemetrexed + Cisplatin"}],"paramType":"MEDIAN","populationDescription":"All randomized Phase 2 participants.","reportingStatus":"POSTED","timeFrame":"Randomization to the date of death from any cause through the time of study discontinuation (approximately 12 months after last participant was randomized)","title":"Phase 2: Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}